AGEN Stock - Agenus Inc.
Unlock GoAI Insights for AGEN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $103.46M | $156.31M | $98.02M | $295.67M | $88.17M |
| Gross Profit | $-52,551,000 | $-81,366,000 | $-99,235,000 | $113.59M | $-56,796,000 |
| Gross Margin | -50.8% | -52.1% | -101.2% | 38.4% | -64.4% |
| Operating Income | $-120,475,000 | $-159,549,000 | $-179,427,000 | $25.75M | $-117,235,000 |
| Net Income | $-227,212,000 | $-245,761,000 | $-220,074,000 | $-23,926,000 | $-180,914,000 |
| Net Margin | -219.6% | -157.2% | -224.5% | -8.1% | -205.2% |
| EPS | $-10.59 | $-13.75 | $-15.64 | $-2.11 | $-21.00 |
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 4th 2025 | H.C. Wainwright | Upgrade | Buy | $25 |
| July 19th 2024 | Robert W. Baird | Downgrade | Neutral | $8← $35 |
| July 18th 2024 | William Blair | Downgrade | Market Perform | - |
| July 18th 2024 | H.C. Wainwright | Downgrade | Neutral | $9 |
| June 6th 2023 | Robert W. Baird | Initiation | Outperform | $80← $60 |
| February 28th 2023 | H.C. Wainwright | Resumed | Buy | $8 |
| September 28th 2022 | SMBC Nikko | Initiation | Outperform | $5 |
Earnings History & Surprises
AGENEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | $1.29 | — | — | — |
Q4 2025 | Nov 10, 2025 | $2.63 | $1.94 | -26.2% | ✗ MISS |
Q3 2025 | Aug 11, 2025 | $-0.78 | $-1.00 | -28.2% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-1.61 | $-1.03 | +36.0% | ✓ BEAT |
Q1 2025 | Mar 11, 2025 | $-2.36 | $-2.04 | +13.6% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-2.33 | $-3.08 | -32.2% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-1.44 | $-2.52 | -75.0% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-3.22 | $-3.04 | +5.6% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $-0.40 | $-2.60 | -550.0% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-3.80 | $-3.20 | +15.8% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-4.00 | $-4.00 | 0.0% | = MET |
Q2 2023 | May 9, 2023 | $-4.20 | $-4.40 | -4.8% | ✗ MISS |
Q1 2023 | Mar 14, 2023 | $-4.40 | $-4.80 | -9.1% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-3.60 | $-3.80 | -5.6% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-4.60 | $-3.40 | +26.1% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-5.80 | $-3.80 | +34.5% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-3.20 | $-5.20 | -62.5% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $9.20 | $13.80 | +50.0% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-4.80 | $-7.40 | -54.2% | ✗ MISS |
Latest News
Agenus Q3 EPS $1.94 Misses $1.98 Estimate, Sales $30.200M Miss $55.713M Estimate
📉 NegativeAgenus Releases New Data From Its botensilimab And balstilimab Combination Showing Durable Survival Benefits Across Multiple Late-Stage, Treatment-Resistant Cancers And That ~40% Of Patients With Very Limited Survival Expectation Are Alive At Two Years
📈 PositiveAgenus Says Closing Of Deals With Zydus Pharmaceuticals Shifted To Q4 2025
➖ NeutralHC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
📈 PositiveAgenus Says Investigational Combination BOT/BAL Now Available To Eligible Patients With Refractory MSS mCRC Under France's Compassionate Access Framework
📈 PositiveHC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
📈 PositiveAgenus to Host Aug. 27 Virtual Briefing Highlighting Cancer Drug Pipeline and Phase 3 CRC Study
📈 PositiveAgenus Posts 48% Q2 Revenue Miss
📉 NegativeAgenus unit, MiNK surges after peer-reviewed data for lead drug
📈 PositiveAgenus climbs on deal with India's Zydus for cancer therapy BOT/BAL
📈 PositiveFrequently Asked Questions about AGEN
What is AGEN's current stock price?
What is the analyst price target for AGEN?
What sector is Agenus Inc. in?
What is AGEN's market cap?
Does AGEN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AGEN for comparison